Related Experiment Videos
Multidisciplinary approach to cost reduction of C-section prophylaxis
A hospital faced high costs from cefoxitin used during C-sections. The P & T Committee and pharmacy team evaluated usage and found C-sections accounted for 25% of cefoxitin use. They worked with the ob/gyn department to switch to a cheaper alternative, cefotetan, for six months. This saved about $49,086 annually without affecting patient outcomes. A second trial compared cefotetan with cefazolin, and both were equally effective. Cefazolin replaced cefotetan, adding $10,384 in savings. Overall, the hospital saved $59,470 by changing antibiotics. The authors suggest this multidisciplinary approach can help other hospitals reduce costs while keeping patients safe.
Area of Science:
- Hospital pharmacy management
- Antibiotic stewardship in obstetrics
Background:
Antibiotic costs in surgical procedures remain a significant financial burden for hospitals. Prior research has shown that prophylactic antibiotic use during C-sections is common but often subject to cost fluctuations. No prior work had resolved how to maintain patient safety while reducing expenses. This gap motivated a hospital to evaluate its C-section prophylaxis strategy. The P & T Committee identified cefoxitin as a costly agent. Usage patterns revealed that nearly a quarter of all cefoxitin was consumed during C-sections. The ob/gyn department was engaged to assess alternative regimens. The goal was to identify a more affordable but equally effective option.
Purpose Of The Study:
The study aimed to reduce the financial burden of C-section prophylaxis without compromising patient outcomes. The P & T Committee identified cefoxitin as a high-cost antibiotic. The ob/gyn department was tasked with changing prescribing practices. A trial replaced cefoxitin with cefotetan for a six-month period. The team sought to measure cost savings and monitor any changes in morbidity. The antibiotic review subcommittee requested a second trial to compare cefotetan with cefazolin. The objective was to find the most cost-effective single-dose option. The overall goal was to demonstrate a multidisciplinary cost-reduction model.
Main Methods:
The P & T Committee initiated a usage evaluation of cefoxitin. The antibiotic review subcommittee collaborated with the pharmacy department. The ob/gyn department was involved in changing prescribing habits. A six-month trial replaced multidose cefoxitin with single-dose cefotetan. Drug and supply costs were tracked to measure savings. Morbidity rates were compared before and after the change. A second trial compared cefotetan with cefazolin in C-section patients. Outcomes were analyzed to determine which option was more cost-effective.
Main Results:
The cefoxitin-to-cefotetan switch saved approximately $49,086 annually. No increase in postoperative complications was observed. The second trial showed cefazolin and cefotetan had similar effectiveness. Cefazolin replaced cefotetan, adding $10,384 in savings. Total annual savings reached $59,470. The multidisciplinary approach proved successful in reducing costs. Patient safety was maintained throughout the trials. The results suggest that cost-effective alternatives exist without compromising outcomes.
Conclusions:
The authors propose that a multidisciplinary strategy can reduce C-section prophylaxis costs. The switch from cefoxitin to cefotetan and then to cefazolin saved nearly $60,000. No adverse effects on patient outcomes were reported. The P & T Committee and ob/gyn department collaboration was key. The antibiotic review subcommittee played a central role in evaluating alternatives. The results suggest that cost savings are achievable without compromising care. The authors propose that this model can be applied in other hospitals. The study highlights the importance of coordinated efforts in antibiotic stewardship.
Frequently Asked Questions
The approach saved $59,470 annually without affecting patient outcomes.
Single-dose cefotetan replaced multidose cefoxitin for a six-month trial.
They were needed to change prescribing habits and evaluate alternative regimens.
They requested a trial to compare cefotetan with cefazolin in C-section patients.
An additional $10,384 was saved after cefazolin replaced cefotetan.
They propose it is effective for reducing C-section prophylaxis costs.